Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease.
Kenta YoshidaAnita MoeinTobias BittnerSusanne OstrowitzkiHelen LinLee HonigbergJin Y JinAngelica L QuartinoPublished in: Alzheimer's research & therapy (2020)
ClinicalTrials.gov, NCT01397578. Registered July 19, 2011. GN29632: ClinicalTrials.gov, NCT02353598. Registered February 3, 2015.
Keyphrases